Amarin Corp
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Amarin Corp
Popular executive movements at Amarin Corp
- Jonathan Provoost will join the company as Executive Vice President and Chief Legal & Compliance Officer on Nov. 15, 2023 (posted on November 1 2023).
Create your alert
to follow the executive moves at Amarin Corp.
Pharmaceuticals
Amarin Corp has 1,863 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Amarin Corp
- Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update | Amarin Corporation plc
- Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022 | Amarin Corporation plc
- NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales | Amarin Corporation plc
- REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo | Amarin Corporation plc
- Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl) | Amarin Corporation plc
- Press Releases | Amarin Corporation plc
- Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business | Amarin Corporation plc
- Amarin Appoints Tom Reilly as New Chief Financial Officer | Amarin Corporation plc
- Amarin Announces Appointment of New Directors and Board Leadership Changes | Amarin Corporation plc
- Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs | Amarin Corp
- View more press releases Close
Social media about Amarin Corp
- Amarin Corp on Wikipedia, Google News & Yahoo Finance
- Amarin Corp on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Patrick Holt 
